{"id":"prourokinase","rwe":[],"tags":[],"trials":[],"_chembl":null,"aliases":["Reocmbinant Human Prourokinase for Injection","TIANJIN TASLY PHARMACEUTICAL CO.,LTD"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":null,"ecosystem":[],"_scrapedAt":"2026-03-27T23:36:47.687Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07389460","phase":"PHASE3","title":"Intravenous rhPro-UK Before Stroke Thrombectomy in the Extended Time Window (BRIDGE-PUK EXTEND)","status":"NOT_YET_RECRUITING","sponsor":"First Affiliated Hospital Xi'an Jiaotong University","startDate":"2026-01-31","conditions":"Acute Ischemic Stroke","enrollment":820},{"nctId":"NCT06115070","phase":"PHASE4","title":"Intravenous Thrombolytic Therapy for Acute Ischemic Stroke Patients with Low NIHSS and Non-disabling Deficits","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-03-01","conditions":"Thrombosis, Acute Ischemic Stroke (AIS)","enrollment":390},{"nctId":"NCT06841965","phase":"PHASE3","title":"Intravenous Thrombolysis in Acute Ischemic Stroke with Active Cancer","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-03-01","conditions":"Stroke, Acute Ischemic Stroke","enrollment":280},{"nctId":"NCT06749834","phase":"PHASE3","title":"Intravenous Thrombolysis and NOAC","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-01-27","conditions":"Acute Ischemic Stroke","enrollment":280},{"nctId":"NCT06841978","phase":"PHASE3","title":"Intravenous Thrombosis and Patients with Prior Ischemic Stroke Within 3 Months","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-03-01","conditions":"Stroke, Acute Ischemic Stroke","enrollment":306},{"nctId":"NCT05507645","phase":"PHASE3","title":"ProUrokinase for Mild Ischemic Cerebrovascular Events (PUMICE)","status":"COMPLETED","sponsor":"Beijing Tiantan Hospital","startDate":"2022-11-15","conditions":"Ischemic Stroke, Mild, Thrombosis","enrollment":1446},{"nctId":"NCT05700591","phase":"PHASE3","title":"rhPro-UK in Acute Ischaemic Stroke Within 4.5 Hours of Stroke Onset Trial 2(PROST-2)","status":"COMPLETED","sponsor":"Tasly Biopharmaceuticals Co., Ltd.","startDate":"2023-01-29","conditions":"Acute Ischemic Stroke","enrollment":1552},{"nctId":"NCT03108833","phase":"PHASE2","title":"A Trial in Recombinant Human Prourokinase to Treat Acute Pulmonary Embolism","status":"COMPLETED","sponsor":"Tasly Biopharmaceuticals Co., Ltd.","startDate":"2017-06-06","conditions":"Acute Pulmonary Embolism","enrollment":108},{"nctId":"NCT01694381","phase":"EARLY_PHASE1","title":"Research Into the Effect of a Clot-dissolving Agent and Its Inhibitor","status":"TERMINATED","sponsor":"TSI, LLC","startDate":"2012-09","conditions":"Acute Ischemic Stroke","enrollment":8},{"nctId":"NCT03541668","phase":"PHASE3","title":"Study of rhPro-UK in Patients With Acute Ischaemic Stroke in 4.5 Hours After Stroke Onset(PROST)","status":"COMPLETED","sponsor":"Tasly Biopharmaceuticals Co., Ltd.","startDate":"2018-05-18","conditions":"Acute Ischaemic Stroke","enrollment":674},{"nctId":"NCT03578822","phase":"PHASE3","title":"Thrombolysis With rhPro-UK in 4.5-6 Hours After Acute Ischemic Stroke in a Double-blinded,Controlled Trial","status":"COMPLETED","sponsor":"Tasly Biopharmaceuticals Co., Ltd.","startDate":"2018-08-10","conditions":"Acute Ischaemic Stroke","enrollment":149},{"nctId":"NCT02131220","phase":"PHASE4","title":"Effects of Intracoronary Prourokinase on the Coronary Flow During Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction","status":"COMPLETED","sponsor":"Fudan University","startDate":"2015-11","conditions":"Myocardial Infarction, Percutaneous Coronary Intervention, Thrombolytic Therapy","enrollment":362},{"nctId":"NCT03137212","phase":"NA","title":"Safety and Efficacy of Percutaneous Coronary Intervention Combined With Thrombolysis at Different Time","status":"UNKNOWN","sponsor":"Second Hospital of Jilin University","startDate":"2017-04-17","conditions":"Acute ST Segment Elevation Myocardial Infarction","enrollment":120},{"nctId":"NCT01642667","phase":"PHASE2, PHASE3","title":"Pharmacoinvasive Therapy With Prourokinase","status":"COMPLETED","sponsor":"Suzhou Landing Pharmaceuticals","startDate":"2008-11","conditions":"ST-segment Elevation Myocardial Infarction (STEMI)","enrollment":197}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"BRAIN HERNIATION"},{"count":1,"reaction":"CEREBRAL HAEMORRHAGE"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":523,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Prourokinase","genericName":"Prourokinase","companyName":"Suzhou Landing Pharmaceuticals","companyId":"suzhou-landing-pharmaceuticals","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"enriching","dataCompleteness":{"mechanism":false,"indications":false,"safety":false,"trials":true,"score":1}}